Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* Subjects who the investigator believes can and will comply with the requirements of the protocol should be enrolled in the study.~* A male or female between, and including, 18 and 60 years of age at the time of the vaccination.~* Written informed consent obtained from the subject.~* If the subject is female, she must be of non-childbearing potential, if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of the vaccination series.~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the administration of study vaccine, or planned use during the study period.~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within 3 months prior to administration of the vaccine.~* Administration of a vaccine not foreseen in the study protocol from 30 days before vaccination up to 21 days post vaccination.~* Confirmed influenza infection within a year preceding the study start.~* Administration of an influenza vaccine during Northern Hemisphere season 2007-2008.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device).~* History of hypersensitivity to a previous dose of influenza vaccine~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s).~* Acute disease at the time of enrolment.~* Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.~* Administration of immunoglobulins and/or any blood products within the three months preceding the administration of study vaccine or planned administration during the study period.~* Pregnant or lactating female.~* Female planning to become pregnant or planning to discontinue contraceptive precautions.~* History of chronic alcohol consumption and/or drug abuse.~* Any condition which, in the opinion of the investigator, prevents the subject from participating in the study.~* History of administration of experimental/licensed vaccine.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Quadrivalent influenza vaccine GSK 2115160A Group 1 (Type: EXPERIMENTAL): Subjects in this group received 1 full dose of GSK Biologicals' quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
- Quadrivalent influenza vaccine GSK 2115160A Group 2 (Type: EXPERIMENTAL): Subjects in this group received 1 low dose of GSK Biologicals' quadrivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
- Trivalent influenza vaccine GSK 2115160A Group 1 (Type: ACTIVE_COMPARATOR): Subjects in this group received 1 low dose of GSK Biologicals' trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0
- Trivalent influenza vaccine GSK 2115160A Group 2 (Type: ACTIVE_COMPARATOR): Subjects in this group received 1 full dose of GSK Biologicals' trivalent influenza vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, at Day 0

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete